EUVIMEDEUVIMED entdecken
Crossref

Idelalisib modulates CD4+ T cell responses to mitigate rejection of allografts in mice

Weiqi Zhang, Xiaohan Zhang, Lu Hu, Shuai Jin, Leonard Pitts, Markus Kofler, Zhihong Wang, Jasper Iske, Yeqi Nian, Zhongyang Shen

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Weiqi Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China; Department of Kidney Transplant, Tianjin First Cent…. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Graft Rejection, Heart Transplantation, Quinazolinones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Berlin Institute of Health, Tianjin Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune rejection remains a leading cause of graft loss following organ transplantation, with CD4+ T cells playing a central role in this process. The PI3K/AKT/mTOR signaling pathway is essential for the activation, proliferation, and metabolic reprogramming of CD4+ T cells, making it an attractive therapeutic target. However, the role of Idelalisib (ID), a selective PI3Kδ inhibitor, in transplant immunity remains underexplored. METHODS: Purified CD4+ T cells from the spleens of C57BL/6 mice were cultured with ID. Activation, proliferation, differentiation and survival were evaluated. A fully mismatched skin and heart transplantation model was used to assess ID's effects on rejection. Histopathology analysis and transcriptomic sequencing were performed. RESULTS: ID significantly suppressed CD4+ T cell activation, proliferation, and Th1 differentiation, while enhancing cell survival-contrasting with the pro-apoptotic effects observed with the mTOR inhibitor rapamycin (Rapa). In the skin and heart transplantation models, ID reduced acute rejection, extended graft survival, and decreased the proliferation of CD4+ T cells and B cells. Transcriptomic analysis revealed downregulation of genes involved in T cells activation and differentiation (e.g., Zap70, Stat4), as well as markers of glycolysis (e.g., Gapdh, Pfkm). Functional assays confirmed reduced glucose uptake and lactate production in ID-treated cells. CONCLUSIONS: ID uniquely modulates T cell responses through PI3Kδ inhibition, providing a distinct immunosuppressive mechanism from that of mTOR inhibitors. These findings highlight the therapeutic potential of ID in preventing transplant rejection and reveal a critical link between PI3K signaling and CD4+ T cell metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD4-Positive T-LymphocytesGraft RejectionHeart TransplantationQuinazolinonesPurinesSkin TransplantationImmunosuppressive AgentsAnimalsMice, Inbred C57BLMiceCell ProliferationLymphocyte ActivationGraft SurvivalAllograftsMaleCells, CulturedSignal Transduction

Stichwörter der Autor:innen

Alloimmune responseCD4(+) T cellsIdelalisibTransplant rejection

Substanzen

QuinazolinonesPurinesidelalisibImmunosuppressive Agents

Autor:innen und Institutionen

  • Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China; Department of Kidney Transplant, Tianjin First Central Hospital, Tianjin, China.
  • Department of Kidney Transplant, Tianjin First Central Hospital, Tianjin, China; Tianjin Medical University First Central Clinical College, Tianjin, China.
  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany; Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Ch…
  • Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China.
  • Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China; Department of Kidney Transplant, Tianjin First Central Hospital, Tianjin, China. Electronic address: nianyeqi0314@hotmail…
  • Research Institute of Transplant Medicine, School of Medicine, Nankai University, Tianjin, China; Department of Kidney Transplant, Tianjin First Central Hospital, Tianjin, China. Electronic address: zhongyangshen@nankai…

Förderung

  • National Natural Science Foundation of China
  • Berlin Institute of Health
  • Tianjin Municipal Natural Science Foundation

Zitieren

APA

Zhang, W., Zhang, X., Hu, L., Jin, S., Pitts, L., Kofler, M., Wang, Z., Iske, J., Nian, Y., & Shen, Z. (2025). Idelalisib modulates CD4+ T cell responses to mitigate rejection of allografts in mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115155

Vancouver

Zhang W, Zhang X, Hu L, Jin S, Pitts L, Kofler M, et al. Idelalisib modulates CD4+ T cell responses to mitigate rejection of allografts in mice. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115155

BibTeX
@article{Zhang2025,
  author = {Zhang, Weiqi and Zhang, Xiaohan and Hu, Lu and Jin, Shuai and Pitts, Leonard and Kofler, Markus and Wang, Zhihong and Iske, Jasper and Nian, Yeqi and Shen, Zhongyang},
  title = {Idelalisib modulates CD4+ T cell responses to mitigate rejection of allografts in mice},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115155}
}
Kostenlos starten →